{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:50:36Z","timestamp":1792050636198,"version":"4.4.0"},"reference-count":61,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>In the treatment of cancer, immune checkpoint inhibitors (ICIs) have demonstrated significantly greater effectiveness compared to conventional cytotoxic or platinum-based chemotherapies. To assess the efficacy of ICI\u2019s in penile squamous cell carcinoma (pSCC) we performed a retrospective observational study. We reviewed electronic medical records of patients with penile squamous cell carcinoma (SCC), diagnosed between January 2020 and February 2023. Nine patients were screened, of whom three were ineligible for chemotherapy and received immunotherapy, cemiplimab, in a first-line setting. Each of the three immunotherapy-treated patients achieved almost a complete response (CR) after only a few cycles of therapy. The first patient had cerebral arteritis during treatment and received a high-dose steroid treatment with resolution of the symptoms of arteritis. After tapering down the steroids dose, the patient continued cemiplimab without further toxicity. The other two patients did not have any toxic side effects of the treatment. To the best of our knowledge, this is the first real world report of near CR with cemiplimab as a first-line treatment in penile SCC.<\/jats:p>","DOI":"10.3390\/jpm13111623","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T10:32:32Z","timestamp":1700476352000},"page":"1623","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Cemiplimab as First Line Therapy in Advanced Penile Squamous Cell Carcinoma: A Real-World Experience"],"prefix":"10.3390","volume":"13","author":[{"given":"Keren","family":"Rouvinov","sequence":"first","affiliation":[{"name":"The Legacy Heritage Center & Dr. Larry Norton Institute, Soroka Medical Center and Ben Gurion University, Beer Sheva 84105, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gal","family":"Mazor","sequence":"additional","affiliation":[{"name":"Medical School for International Health, Ben Gurion University of the Negev, Beer Sheva 84105, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Kozlener","sequence":"additional","affiliation":[{"name":"Department of Oncology, Bnei Zion Medical Center, Haifa 31048, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amichay","family":"Meirovitz","sequence":"additional","affiliation":[{"name":"The Legacy Heritage Center & Dr. Larry Norton Institute, Soroka Medical Center and Ben Gurion University, Beer Sheva 84105, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa Shani","family":"Shrem","sequence":"additional","affiliation":[{"name":"The Legacy Heritage Center & Dr. Larry Norton Institute, Soroka Medical Center and Ben Gurion University, Beer Sheva 84105, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Abu Saleh","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Emek Medical Centre, Afula 18341, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sondos","family":"Shalata","sequence":"additional","affiliation":[{"name":"Nutrition Unit, Galilee Medical Center, Nahariya 22000, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Yakobson","sequence":"additional","affiliation":[{"name":"The Legacy Heritage Center & Dr. Larry Norton Institute, Soroka Medical Center and Ben Gurion University, Beer Sheva 84105, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7570-4550","authenticated-orcid":false,"given":"Walid","family":"Shalata","sequence":"additional","affiliation":[{"name":"The Legacy Heritage Center & Dr. Larry Norton Institute, Soroka Medical Center and Ben Gurion University, Beer Sheva 84105, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1038\/s41598-020-59831-5","article-title":"Profile of patients with penile cancer in the region with the highest worldwide incidence","volume":"10","author":"Vieira","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_2","first-page":"e117","article-title":"Incidence of penile cancer worldwide: Systematic review and meta-analysis","volume":"41","year":"2017","journal-title":"Rev. Panam. Salud Publica"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-021-00246-5","article-title":"Penile cancer","volume":"7","author":"Thomas","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_4","unstructured":"Douglawi, A., and Masterson, T.M. (2022, September 07). Opinion in Urology, and Undefined 2019: Penile Cancer Epidemiology and Risk Factors: A Contemporary Review. Available online: https:\/\/journals.lww.com\/co-urology\/Fulltext\/2019\/03000\/Penile_cancer_epidemiology_and_risk_factors__a.14.aspx."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1097\/00000478-200311000-00007","article-title":"Lichen sclerosus in 68 patients with squamous cell carcinoma of the penis: Frequent atypias and correlation with special carcinoma variants suggests a precancerous role","volume":"27","author":"Velazquez","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_6","first-page":"646","article-title":"The Diagnosis and Treatment of Penile Cancer","volume":"115","author":"Hakenberg","year":"2018","journal-title":"Dtsch Arztebl Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/imr.12531","article-title":"Introduction to Checkpoint Inhibitors and Cancer Immunotherapy","volume":"276","author":"Sharpe","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"El Zarif, T., Nassar, A.H., Pond, G.R., Zhuang, T.Z., Master, V., Nazha, B., Niglio, S., Simon, N., Hahn, A.W., and Pettaway, C.A. (2023). Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: Report from the Global Society of Rare Genitourinary Tumors. J. Natl. Cancer Inst., djad155. Epub ahead of print.","DOI":"10.1093\/jnci\/djad155"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.euf.2019.02.019","article-title":"Defining the Tumor Microenvironment of Penile Cancer by Means of the Cancer Immunogram","volume":"5","author":"Ottenhof","year":"2019","journal-title":"Eur. Urol. Focus"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/MOU.0000000000000712","article-title":"Risk factors and molecular characterization of penile cancer: Impact on prognosis and potential targets for systemic therapy","volume":"30","author":"Thomas","year":"2020","journal-title":"Curr. Opin. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Shalata, W., Yakobson, A., Cohen, A.Y., Goldstein, I., Saleh, O.A., Dudnik, Y., and Rouvinov, K. (2023). Unexpected Adverse Events of Immune Checkpoint Inhibitors. Life, 13.","DOI":"10.3390\/life13081657"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Yakobson, A., Abu Jama, A., Abu Saleh, O., Michlin, R., and Shalata, W. (2023). PD-1 Inhibitors in Elderly and Immunocompromised Patients with Advanced or Metastatic Cutaneous Squamous Cell Carcinoma. Cancers, 15.","DOI":"10.3390\/cancers15164041"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Yakobson, A., Rouvinov, K., Cohen, A.Y., Goldstein, I., Abu Saleh, O., Solomon, A., Dudnik, Y., and Shalata, W. (2023). Carpal Tunnel Syndrome Associated with Immune Checkpoint Inhibitors. J. Pers. Med., 13.","DOI":"10.3390\/jpm13091340"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1159\/000517008","article-title":"Cemiplimab for cisplatin resistant metastatic penile cancer","volume":"14","author":"Denis","year":"2021","journal-title":"Case Rep. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"615298","DOI":"10.3389\/fonc.2020.615298","article-title":"Case report: Two cases of chemotherapy refractory metastatic penile squamous cell cancinoma with extreme durable response to pembrolizumab","volume":"10","author":"Chahoud","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_17","first-page":"90","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE\u2014Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies","volume":"112","author":"Santana","year":"2021","journal-title":"Actas Dermosifiliogr."},{"key":"ref_18","unstructured":"National Comprehensive Cancer Network (2023, February 20). NCCN Clinical Practice Guidelines in Oncology: Penile Cancer, Version 1.2023. Available online: https:\/\/www.nccn.org\/guidelines\/category_1."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijrobp.2013.08.013","article-title":"Stage presentation, care patterns, and treatment outcomes for squamous cell carcinoma of the penis","volume":"88","author":"Burt","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1590\/abd1806-4841.20175009","article-title":"Penile squamous cell carcinoma: A review of the literature and case report treated with Mohs micrographic surgery","volume":"92","author":"Marchionne","year":"2017","journal-title":"An. Bras. Dermatol."},{"key":"ref_21","first-page":"361","article-title":"Incidence trends in primary malignant penile cancer [published correction appears in Urol Oncol. 2008 Jan-Feb;26:112. Guiliano, Anna R [corrected to Giuliano, Anna R]]","volume":"25","author":"Maldonado","year":"2007","journal-title":"Urol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/dsu.12029","article-title":"Malignant tumors of the penis","volume":"39","author":"Brady","year":"2013","journal-title":"Dermatol. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.euf.2018.09.010","article-title":"The role of human papilloma virus in penile cancer prevention and new therapeutic agents","volume":"5","author":"Schlenker","year":"2019","journal-title":"Eur. Urol. Focus"},{"key":"ref_24","unstructured":"U.S. Food & Drug Administration (2023, February 14). FDA Approves Cemiplimab-Rwlc for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-cemiplimab-rwlc-metastatic-or-locally-advanced-cutaneous-squamous-cell-carcinoma."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_26","unstructured":"National Institute of Health (2023, February 22). Study of Cemiplimab in Patients with Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04154943."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"v462","DOI":"10.1093\/annonc\/mdz252.030","article-title":"First-line versus second-line immunotherapy in recurrent\/metastatic squamous cell carcinoma of the head and neck","volume":"30","author":"Even","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1200\/JCO.18.01896","article-title":"Durable Tumor Regression and Overall Survival in Patients with Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy","volume":"37","author":"Nghiem","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_29","unstructured":"Bsn, R.N.R. (2019, August 23). Immunotherapy Should Be First Line in Merkel Cell Carcinoma. Medscape. Available online: https:\/\/www.medscape.com\/viewarticle\/910547?form=fpf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S1677","DOI":"10.1016\/j.jtho.2017.09.213","article-title":"MS 05.02 First-line versus Second-Line Anti-PD-(L)1 Therapy for Patients with Positive PD-L1 Expression","volume":"12","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.2217\/imt-2023-0039","article-title":"Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: A meta-analysis","volume":"15","author":"Yanagisawa","year":"2023","journal-title":"Immunotherapy"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.21037\/apm-20-449","article-title":"Comparison between the first-line and second-line immunotherapy drugs in the progression-free survival and overall survival in advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Wu","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2018.12.012","article-title":"Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients","volume":"108","author":"Stoff","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1158\/1078-0432.CCR-18-1116","article-title":"Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations","volume":"24","author":"Kugel","year":"2018","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2019.03.004","article-title":"Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma","volume":"113","author":"Kacew","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/annonc\/mdw216","article-title":"Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: Potential opportunities for immunotherapeutic approaches","volume":"27","author":"Udager","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1159\/000507278","article-title":"Associated Myocarditis: A Predictive Factor for Response?","volume":"13","author":"Shalata","year":"2020","journal-title":"Case Rep. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1111\/1759-7714.13149","article-title":"Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer","volume":"10","author":"Komiya","year":"2019","journal-title":"Thorac. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Shalata, W., Zolnoorian, J., Migliozzi, G., Jama, A.A., Dudnik, Y., Cohen, A.Y., Meirovitz, A., and Yakobson, A. (2023). Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065938"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/1759-7714.13364","article-title":"Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer","volume":"11","author":"Sugano","year":"2020","journal-title":"Thorac. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Wright, Q., Cruz, J.L.G., Wells, J.W., and Leggatt, G.R. (2021). PD-1 and beyond to Activate T Cells in Cutaneous Squamous Cell Cancers: The Case for 4-1BB and VISTA Antibodies in Combination Therapy. Cancers, 13.","DOI":"10.3390\/cancers13133310"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00262-020-02558-z","article-title":"PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1\/PD-L1 blockade","volume":"69","author":"Trefny","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Pesce, S., Trabanelli, S., Di Vito, C., Greppi, M., Obino, V., Guolo, F., Minetto, P., Bozzo, M., Calvi, M., and Zaghi, E. (2020). Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes. Cancers, 12.","DOI":"10.3390\/cancers12123504"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e1537581","DOI":"10.1080\/2162402X.2018.1537581","article-title":"Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients","volume":"8","author":"Lee","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Shalata, W., Yakobson, A., Dudnik, Y., Swaid, F., Ahmad, M.S., Abu Jama, A., Cohen, A.Y., and Agbarya, A. (2023). Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer. Biomedicines, 11.","DOI":"10.3390\/biomedicines11092438"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"731798","DOI":"10.3389\/fphar.2021.731798","article-title":"PD-1\/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Shalata, W., Weissmann, S., Itzhaki Gabay, S., Sheva, K., Abu Saleh, O., Jama, A.A., Yakobson, A., and Rouvinov, K. (2022). A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors. Cancers, 14.","DOI":"10.3390\/cancers14215451"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Shalata, W., Abu-Salman, A., Steckbeck, R., Mathew Jacob, B., Massalha, I., and Yakobson, A. (2021). Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review. Cancers, 13.","DOI":"10.3390\/cancers13205218"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Shalata, W., Iraqi, M., Bhattacharya, B., Fuchs, V., Roisman, L.C., Cohen, A.Y., Massalha, I., Yakobson, A., Prasad, M., and Elkabets, M. (2021). Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma). Cancers, 13.","DOI":"10.3390\/cancers13143630"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/10408360902937809","article-title":"Cancer immunotherapy","volume":"46","author":"Baxevanis","year":"2009","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/EDBK_156572","article-title":"Basic Overview of Current Immunotherapy Approaches in Cancer","volume":"35","author":"Velcheti","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1061761","DOI":"10.3389\/fimmu.2023.1061761","article-title":"Evaluation of immunotherapy efficacy in gynecologic cancer","volume":"14","author":"Jiang","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients\u2019 sex: A systematic review and meta-analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_56","first-page":"217","article-title":"Developments in immunotherapy for gastrointestinal cancer","volume":"70","author":"Diaz","year":"2015","journal-title":"Minerva Chir."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"15421","DOI":"10.18632\/oncotarget.7304","article-title":"Improving the clinical impact of biomaterials in cancer immunotherapy","volume":"7","author":"Gammon","year":"2016","journal-title":"Oncotarget"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2217\/imt-2022-0035","article-title":"Tsunami of immunotherapies in the management of esophageal cancer","volume":"14","author":"Kassab","year":"2022","journal-title":"Immunotherapy"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.3748\/wjg.v25.i24.2977","article-title":"Immunotherapy for hepatocellular carcinoma: Current and future","volume":"25","author":"Johnston","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/bfgp\/ely022","article-title":"Cancer immunotherapy for metastasis: Past, present and future","volume":"18","author":"Wang","year":"2019","journal-title":"Brief Funct. Genom."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/GRF.0000000000000513","article-title":"Immunotherapy for Gynecologic Cancer: Current Applications and Future Directions","volume":"63","author":"Lynam","year":"2020","journal-title":"Clin. Obstet. Gynecol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/11\/1623\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:26:26Z","timestamp":1760131586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/11\/1623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,20]]},"references-count":61,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["jpm13111623"],"URL":"https:\/\/doi.org\/10.3390\/jpm13111623","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,20]]}}}